跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
CIMA-AEMPS
/
SKYRIZI 600 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Approved
STANDARD
SKYRIZI 600 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Abbvie Deutschland Gmbh & Co. Kg
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Dec 15, 2022
Approval ID
fb52d1071111c4d1
Company
Abbvie Deutschland Gmbh & Co. Kg
Type
Standard
Approval Details
Approval Id
fb52d1071111c4d1
Drug Cima Aemps Name
SKYRIZI 600 MG CONCENTRADO PARA SOLUCION PARA PERFUSION
Register Number
1191361004
Holder Company Name
Abbvie Deutschland Gmbh & Co. Kg
Marketing Company Name
Abbvie Spain, S.L.U.
Holder Company Detail Path
/organization/abbvie-deutschland-gmbh-and-co-kg
Authorization Date
2022-12-15
Dosage Form
CONCENTRADO PARA SOLUCIÓN PARA PERFUSIÓN
Dose
600 MG
Route Of Administration
VÍA INTRAVENOSA
Prescription Type
Uso Hospitalario
Commercialized
Yes
Company Name
Abbvie Deutschland Gmbh & Co. Kg
Company Detail Path
/organization/abbvie-deutschland-gmbh-and-co-kg
Company Information
Pharmaceutical Company Name
AbbVie Deutschland GmbH & Co. KG
Country Name
Germany
City Name
ludwigshafen am rhein,rheinland-pfalz,country_de
Address
Knollstr. 50
Website
http://www.abbvie.de
Active Ingredients
RISANKIZUMAB
600 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Dec 15, 2022
Approval ID
fb52d1071111c4d1
Type
Standard
Back to CIMA-AEMPS Approvals
SKYRIZI 600 MG CONCENTRADO PARA SOLUCION PARA PERFUSION - CIMA-AEMPS Drug Approval Details